US › Healthcare

Akari Therapeutics PLC (AKTX)

US · Healthcare · Biotechnology

$9.88-2.42%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-4.8M

EPS

$-2.69

EPS estimate

$-1.04

EPS came in at -2.69 against a street estimate of -1.04 — a miss of 158.5%.

Key statistics

Market cap

$20.0M

P/E

0.0

Forward P/E

0.0

P/B

1.17

Book value

$10.62

EPS (TTM)

$0.00

52-week high

$49.60

52-week low

$3.02

50-day MA

$9.66

200-day MA

$9.67

Beta

1.43

Analyst view

Analysts rate Akari Therapeutics PLC a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $28.50.

Shareholding

Insiders

15.55%

Institutions

12.22%

Largest institutional holders

Fund	Stake
Armistice Capital, LLC	0.06%
Cresset Asset Management, LLC	0.03%
IFP Advisors, LLC	0.00%
SBI Securities Co Ltd	0.00%
Morgan Stanley - Brokerage Accounts	0.00%
Truvestments Capital LLC	0.00%
Palo Alto Investors, LLC	0.00%
CWA Asset Management Group, LLC	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Akari Therapeutics PLC — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.